HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Morgan, A. J. Articles by Morein, B. Search for Related Content PubMed PubMed Citation Articles by Morgan, A. J. Articles by Morein, B. Agricola Articles by Morgan, A. J. Articles by Morein, B.

Prevention of Epstein-Barr (EB) Virus-induced Lymphoma in Cottontop Tamarins by Vaccination with the EB Virus Envelope Glycoprotein gp340 Incorporated into Immune-stimulating Complexes

¹ Department of Pathology, University of Bristol Medical School, Bristol BS8 1TD, U.K.
and² Section of Virology, Department of Veterinary Microbiology, Swedish University of Agricultural Sciences, BMC Box 585, S-751 23 Uppsala, Sweden

Experimental induction of malignant lymphomas can be achieved in the cottontop tamarin by inoculation with Epstein-Barr (EB) virus. This system provides an animal model for assessing the efficacy of vaccine protection against the virus which is intended to reduce the incidence of human tumours associated with EB virus infection, namely endemic Burkitt's lymphoma and undifferentiated nasopharyngeal carcinoma. Cottontop tamarins have been vaccinated with the major envelope glycoprotein of EB virus, gp340, incorporated into immune-stimulating complexes (iscoms) and were thereby protected against a 100% lymphomagenic dose of virus. The gp340 iscoms are highly immunogenic, requiring only a few micrograms of immunogen to induce protective immunity and thus would be a strong candidate for further development as an EB virus vaccine for use in man.

Keywords: EBV, lymphoma, immune-stimulating complex

Received 11 February 1988; accepted 5 May 1988.

This article has been cited by other articles:

				R. Khanna, M. Sherritt, and S. R. Burrows EBV Structural Antigens, gp350 and gp85, as Targets for Ex Vivo Virus-Specific CTL During Acute Infectious Mononucleosis: Potential Use of gp350/gp85 CTL Epitopes for Vaccine Design J. Immunol., March 1, 1999; 162(5): 3063 - 3069. [Abstract] [Full Text] [PDF]